Published in AIDS Weekly, October 19th, 1998
But it's the wave after that which is most likely to be revolutionary, says Harvard researcher Scott Hammer.
"New agents derived from the existing drug classes ... are in development and hopefully will provide potency and activity against drug-resistant strains," Hammer said. "The next true breakthrough, however, will occur when clinically effective agents directed at new targets become a reality."
Hammer spoke in a plenary address to the American Society for Microbiology's 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 24-27,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.